OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
	369
May Infographic	251
Movement Disorders: Volume 40, Number 6, June 2025	179
Movement Disorders: Volume 40, Number 2, February 2025	121
John Michael Walshe (April 24, 1920–October 14, 2022)	120
Issue Information	119
In Memoriam Mahlon R. DeLong (1938–2024)	116
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism	114
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 12	104
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia	97
The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?	86
Assessing Intronic Variable Number Tandem Repeat ( VNTR) Expansions of the HSF1	82
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy	80
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy	77
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials	76
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease	72
Multimodal Imaging Investigation of the Dentato‐Thalamo‐Cortical Pathway in Friedreich's Ataxia	72
Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease	70
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?	70
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia	67
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers	66
Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in H	65
Biallelic Variants in SLC27A3 Cause a Complex Form of Neurodegeneration with Brain Iron Accumulati	63
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease	62
Indirect Striatal Projection Neurons Drive a D2 Receptor‐Dependent Pathway to Dyskinesia and Dystonia	62

A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase	60
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease	59
Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals	58
Risk Factors for the Diagnosis of Progressive Supranuclear Palsy in the UK Biobank	57
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure	55
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation	55
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism	54
Reply to: “Early Indian Age at Onset of Parkinson's: A Case for a Gene‐Environment Lens”	54
Functional Movement Disorders and Drug‐Induced Movement Disorders	51
Author Index	51
A CGG Repeat Expansion in CSNK1E Associated wit	50
Reply to: “Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected”	50
Stress in Musicians with and Without Focal Dystonia Is Not Reflected in Limbic Circuit Activation	50
Issue Information	50
Thank you to Reviewers 2022	49
	48
Issue Information	48
Obituary for Jan O. Aasly (1950–2022)	48
Movement Disorders: Volume 37, Number 9, September 2022	48
Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder	47
Author Response to Comment on “Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations”	45
Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort	45
Movement Disorders Thanks Journal Reviewers from 2025	44
Safeguarding Advanced Therapies—The Dangers of Therapeutic Neuroabandonment: How Should We Ensure Patient Safety and Scientific Integrity When a Commercial Clinical Trial Sponsor Becomes Insolvent?	43
Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double‐Blinded Evaluation	42
Dystonia	42
AI, Technology, Telemedicine	42
The Lows of High Reward: Choking Under Pressure	41
Genetic Variation Analysis of Essential Tremor: Insights from the China Essential Tremor Alliance Cohort	41
Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search	41
Erratum to “Paired deep brain stimuli elicit short‐term facilitation in globus pallidus interna and subthalamic nucleus”	41
Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and ¹⁸F‐Fluorodopa‐Positron Emission Tomography	41
Novel In‐Frame FGF14 Deletion Causes Spinocerebellar Ataxia Type 27A: Clinical Response to Deep Brain Stimulation and 4‐Aminopyridine	41
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease	41
Substantiating the Short Burst Duration in Cortical Myoclonus	40
Re‐emergent Tremor in Parkinson's Disease: Evidence of Pathologic β and Prokinetic γ Activity	39
Patients with Allan‐Herndon‐Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment	39
Friedreich's Ataxia in Colombia: A Population‐Based Study of Incidence and Socioeconomic Determinants	38
Compound Heterozygous Structural Variants in Cases with Unsolved PRKN ‐Associated Parkinson's Dise	38
Alkaline Phosphatases: A Potential Cause of Variability in Therapeutic Response to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion?	38
Plant‐Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank	37
STUB1 ( SCA48 )/	37
Neurodevelopmental Disorder and Cortical Myoclonus in ZMYM2 Deficiency	37
[ ¹¹ C ]( R )‐	37
Clinical Outcome Assessments for Functional Performance in Spastic Paresis: Systematic Review, Critique, and Recommendations	36
Lesion of the Subthalamic Nucleus Should Not be Labeled “Subthalamotomy”; A Plea for Anatomical Accuracy and Compliance with Historical Legacy	36
Research Priorities on the Role of α‐ Synuclein in Parkinson's Disease Pathogenesis	35
Exploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies	35
Brain–Computer Interface Improves Symptoms of Isolated Focal Laryngeal Dystonia: A Single‐Blind Study	35
Cortical Functional Connectivity Changes in the Body‐First and Brain‐First Subtypes of Parkinson's Disease	35

Apolipoprotein E Polymorphism Is Associated with Age of Onset and Neuropathology in Colony Stimulating Factor 1 Receptor‐Related Disorder	34
Pre‐Diagnostic Factors Associated with Coding‐Based Incident Multiple System Atrophy: A Nested Case–Control Study of the UK Biobank	34
Distal Electroacupuncture Modulates Maladaptive Brainstem and Motor Cortex Plasticity to Alleviate Hemifacial Spasm	33
Genotype–Phenotype Correlations for ATX‐TBP (SCA17): MDSGene Systematic Review	33
Bilateral Globus Pallidus Deep Brain Stimulation Improves Motor Function in ADCY5 ‐Related Disorde	33
Rapid Eye Movement Sleep Behavior Disorder with Clinical Dementia with Lewy Bodies Phenotype but Lacking Postmortem Central Nervous System Synuclein Pathology: Alternate Etiologies	33
Low/High Multi‐Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease	32
Prediction of Pathological Subthalamic Nucleus Beta Burst Occurrence in Parkinson's Disease	32
¹⁸F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies	32
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review	32
Target‐Dependent Postoperative Weight Gain after Pallidothalamic Tractotomy versus Pallidotomy for Dystonia	31
Unilateral Magnetic Resonance‐Guided Focused Ultrasound (MRgFUS) Pallidothalamic Tractotomy in Parkinson's Disease: Promising Results But Uncertain T	31
Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Administration	31
Epigenetic Drug Effects in Levodopa‐Treated Patients with Parkinson's Disease	30
February Infographic	30
Issue Information	30
Unusual Age‐Dependent Behavior of Leukocytes Telomere Length in Friedreich's Ataxia	30
August Infographic	30
Deciphering the Janus‐Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis	30
Digging into the Unknowns of the Human Genome Sequence: The T2T‐CHM13 Reference Assembly Release	30
Parkinsonisms	30
Issue Information	30
Structural Alterations in the Gray Matter Volume in Rapid‐Onset Dystonia‐Parkinsonism	29
Neurodegeneration with Brain Iron Accumulation Disorders and Retinal Neurovascular Structure	29
Keyword Index	29
Movement Disorders: Volume 38, Number 12, December 2023	29
Movement Disorders: Volume 40, Number 3, March 2025	29
Issue Information	29
Static Posture Instability as a Sensitive Biomarker for Motor Abnormalities in Pre‐ataxic Spinocerebellar Ataxia Type 3 Patients	29
Reply to: “Early Onset Nonprogressive Generalized Dystonia Is Caused by Biallelic SHQ1 Variants”	29
Education, History, Disparities, Other Topics	28
Diagnostic Value of Glycocalyx Shedding in Blood for Differentiating between Parkinson's Disease and Multiple System Atrophy	28
Genetic Determined Iron Starvation Signature in Friedreich's Ataxia	28
Corrections to “A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design”	27
Whole‐Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy	27
Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid	27
Correction to “Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus”	27
Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease	27
Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis	27
In Memoriam Gregor K. Wenning (1964–2024)	27
Potential Disease‐Modifying Effects of Ganglioside GM1 Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel‐Group, Double‐Blind, Randomized, Controlled Trial	27
Pallidal Evoked Resonant Neural Activity as a Candidate Biomarker for Deep Brain Stimulation in Dystonia	27
The Self‐Administered Screening Questionnaire for Parkinson's Disease‐Associated Psychosis (SASPAP)	26
GAA ‐ FGF14 Expansions and	26
Sex and Racial/Ethnic Differences in End‐of‐Life Care Preferences in Persons with Parkinson's Disease and Related Disorders	26
Essential Tremor Suppression with a Novel Anti‐Tremor Orthosis: A Randomized Crossover Trial	26
Levodopa Disrupts Activity Patterns and Encoding of Movement in Striatal Cholinergic Interneurons of Behaving Mice	26
Reply to: Patient‐Reported Feedback in Essential Tremor Deep Brain Stimulation: Distinguishing Perceived Comfort from Tremor Suppression	26
Comparison of Two α‐Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism	26
Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease	26
Elevated Plasma Phospho‐Tau217 in Beta‐Propeller Protein‐Associated Neurodegeneration	26
Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease	26
Clearing the Smoke: What Protects Smokers from Parkinson's Disease?	25
June Infographic	25
Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review	25
Pain in Multiple System Atrophy: A Community‐Based Survey	25
CAG Repeat Expansion in THAP11 Is Associated with a Novel Spinocerebellar Ataxia	25
Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease	25
Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease	25
Correction to “Evaluation of Induced Pluripotent Stem Cell‐Derived Dopaminergic Neurons from Siblings with Gaucher Disease Discordant for Parkinsonism”	25
Movement Disorders: Volume 38, Number 9, September 2023	25
Free‐Water Imaging in Friedreich Ataxia Using Multi‐Compartment Models	25
Defining the Importance of Minor Hallucinations in Parkinson's Disease	25
Reply to: Heterogeneity of CSF1R‐RD: Genes, Environment, or Both?	24
	24
September Infographic	24
Glucocerebrosidase Target Engagement and Therapeutic Plasma and Cerebrospinal Fluid Levels After GT ‐02287 Administration in Healthy Volunteers	24
Issue Information	24
Two London Memorials to “James Parkinson [1755–1824], Esq. Surgeon, Late of Hoxton‐Square”	24
The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?	24
February Infographic	24
Learning to Have a Long‐Duration Response	24
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings	24
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study	24
Reply to: Enhancing Clarity in Tremor Network Gene Expression Analysis	23
Proteomic Profiling in Dystonia: The Next Frontier for Pathophysiology Research and Biomarker Exploration	23
Investigating the Brain Mechanisms of Externally Cued Sit‐to‐Stand Movement in Parkinson's Disease	23
Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18‐Year Study	23
Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B	23
Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025	23

Natural Killer Subset Changes and Vascular Endothelial Growth Factor‐A Plasma Profile in Progressive Supranuclear Palsy: The NKscape Study	23
First Evidence for Disease‐Modifying Treatment of SLC20A2‐Related Primary Familial Brain Calcification	23
Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers	23
Movement Disorders: Volume 39, Number 9, September 2024	23
No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts	23
Long‐Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia	22
Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co‐Pathology in Lewy Body Disease	22
GNAO1 Haploinsufficiency: The Milder End of the GNAO1 Phenotypic Spectrum	22
Expanding the Allelic and Clinical Heterogeneity of Movement Disorders Linked to Defects of Mitochondrial Adenosine Triphosphate Synthase	22
Reply to: “Refutation of the αSyn ‐ SAA ‐Based Staging for Parkinson's Progression (Neuronal α‐Syn	22
Diffusion Tensor Imaging‐Along the Perivascular‐Space Index Is Associated with Disease Progression in Parkinson's Disease	22
Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome	22
Longitudinal Clinical and Biological Characteristics in Juvenile‐Onset Huntington's Disease	22
Patient‐Derived Neurons Exhibit α‐Synuclein Pathology and Previously Unrecognized Major Histocompatibility Complex Class I Elevation in Mitochondrial	22
The Global Parkinson's Disease Genetics ( GP2 ) Genome Browser	22
Phenotypical Differentiation of Tremor Using Time Series Feature Extraction and Machine Learning	22
Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease	22
Waveform‐Based Analysis of Head Tremor Using a Marker‐Less Tracking Algorithm with 2D ‐Video: Evaluation of Sinusoidality and Rhythmicity	22
On‐Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial	22
Reply to “Comments on ‘Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets’”	22
Beyond the Homunculus— SCAN ‐ AMN as a Shared Action‐Oriented Neural Substrate across Movement Dis	21
Reply to Letter to the Editor‐MDS‐23‐0498.R2/MDS‐24‐0318.R1	21
Reply to: “Alcohol Intake and Parkinson's Symptoms Following Diagnosis”	21
Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes	21
	21
Automated Motor Tic Detection: A Machine Learning Approach	21
	21
Issue Information	20
Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut	20
Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine Monkey Model of Parkinson's Disease	20
Respiratory Function in Friedreich's Ataxia	20
The Race to Salvage Glucocerebrosidase: Understanding Small‐Molecule Therapies for GBA1 ‐Associate	20
April Infographic	20
Keyword Index	20
Brain Imaging Phenotypes Associated with Polygenic Risk for Essential Tremor	20
Catatonia: What Else Matters?	20
Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell‐Derived A9 Dopaminergic Neurons	20
Movement Disorders: Volume 38, Number 11, November 2023	20
Prasinezumab: A Bayesian Perspective on Its Efficacy	20
March Infographic	20
Step Width Haptic Feedback for Gait Stability in Spinocerebellar Ataxia: Preliminary Results	20
Reply to: “Unravelling the Complexity of VPS16 Splicing: Clinical Implications and Unresolved Ques	20
Clinical Trials in GBA1 ‐Associated Parkinson's Disease: A Need for Molecular Classification	19
Reply to “Prevalence of NOTCH2NLC and FMR1	19
Erythrocytic α‐Synuclein and the Gut Microbiome: Kindling of the Gut‐Brain Axis in Parkinson's Disease	19
Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease	19
Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients	19
The Impact of Calcitriol on Frataxin Levels in Friedreich's Ataxia Patients: Insights and Future Directions	19
Sympathetic Shift and Insular Alteration: Unravelling the Link Between Anxiety and Heart Rate Variability in Parkinson's Disease	19
Reply to: Utility of Progression Rate Since Symptom Onset in Predicting Subsequent Survival in Progressive Supranuclear Palsy	19
Atypical and Other Parkinsonisms	19
A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET	19
Transforming Care Across Countries: Lessons from the Integrated Care Networks for Parkinson's Disease Study ( iCARE ‐ PD	19
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study	19
The Pain in Dystonia Scale (PIDS)—Development and Validation in Cervical Dystonia	19
Authors’ Comments on “Adaptive Deep Brain Stimulation for Parkinson's Disease: Navigating the Roadblocks to Clinical Implementation”	18
Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication‐Refractory Parkinson's Disease Tremor	18
Pathophysiological Role of Primary Motor Cortex in Essential Tremor	18
Automated Quantification of Eye Tics Using Computer Vision and Deep Learning Techniques	18
Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review	18
Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease	18
Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study	18
Novel Variants in DCTN1 Associated with Perry Disease: A Case Series from a Chinese Parkinsonism C	18
Deep Brain Stimulation Improves Parkinson's Disease‐Associated Pain by Decreasing Spinal Nociception	18
Anodal Cerebellar Transcranial Direct Current Stimulation Reduces Motor and Cognitive Symptoms in Friedreich's Ataxia: A Randomized, Sham‐Controlled Trial	18
Functional Magnetic Resonance Imaging (f MRI) Signatures of Progression and Phenoconversion in Prodromal Synucleinopathies	18
Dysautonomia Is Associated with Cognitive Fluctuation in Dementia with Lewy Bodies	17
The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?	17
Movement Disorders: Volume 40, Number 7, July 2025	17
Genetic Analysis of GCA Repeats in the GLS Gene: Implications for Undiagnosed Ataxia and Spinocerebellar Ataxia 3 in Mainland China	17
No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts	17
Top Movement Disorders Journal Reviewers from 2024	17
Globus Pallidus Internus (GPi) Neuromodulation is Not Effective in Unverricht–Lundborg Disease to Control Myoclonia	17
Surgery Imaging and Technology	17
Aggregation‐Seeding Forms of α‐Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid	17
Advancing Parkinson's Research: Considerations and Future Directions	17
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?	17
Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease	16
Computerized Cognitive Training Increases Gray Matter Volumes in Huntington's Disease: A Pilot Study	16
Reply to: “Letter to the Editor by Cao et al.”	16
Reply to: Comment on De Giorgis et al. “Randomized Phase 3 Study of Triheptanoin for Glut1 Deficiency Syndrome–Associated Paroxysmal Movement Disorders”	16
One‐Year Substantia Nigra R2* Changes across Parkinson's Disease Stages	16
Movement Disorders: Volume 41, Number 4, April 2025	16
Cross‐Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease	16
Differences in Sex‐Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism	16
IRF2BPL‐Related Disorder, Causing Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech and Seizures (NEDAMSS) Is Characterized by Pathology Consistent	16
March Infographic	16
Accelerating Medicines Partnership® Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research	16
Shaking Up Ataxia: FGF14 and RFC1 Repeat Expansions in Affected and Unaffected Members of a Chilean Family	16
Further Directions in Mindfulness‐Based Interventions for Tic Disorders	16
Disentangling the Connection Between Neurodevelopment and Neurodegeneration in Huntington's Disease	16
Comments on: “Biallelic ELOVL1 Variants Are Linked to Hypomyelinating Leukodystrophy, Movement Disorder, and Ichthyosis”	15
Spatial Metabolic Covariance Networks in Progressive Supranuclear Palsy: Implications for Symptomatology and Their Neural Basis	15
A Novel α‐Synuclein K58N Missense Variant in a Patient with Parkinson's Disease	15
Beta Burst Characteristics and Coupling within the Sensorimotor Cortical‐Subthalamic Nucleus Circuit Dynamically Relate to Bradykinesia in Parkinson's Disease	15